Attempts to mobilize HSCs by low doses of G-CSF caused severe adverse events and at least one fatality, and was therefore abandoned.66 A Plerixafor-only mobilization trial recently completed in France proved the safety of the drug in an SCD context and provided an estimate of the yield of CD34+ HSPCs in both adult and juvenile patients.67 Plerixafor mobilization has been recently implemented in the ongoing gene therapy clinical trials (see list in Table 2). The gene discussed is CD34; the disease is Schnyder corneal dystrophy.